Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

Beyond Air (XAIR) reported a Q4 loss of $0.09 per share, beating estimates, but missed revenue expectations, reporting $1.15 million versus the $1.39 million consensus. While the EPS loss improved from the prior year, revenues only topped estimates once in the last four quarters, and the stock has underperformed the S&P 500 significantly year-to-date, down nearly 50%. The stock currently holds a Zacks Rank #3 (Hold), indicating market-average performance in the near term, and future performance will depend on earnings estimate revisions and management's commentary.

Analysis

Beyond Air, Inc. (XAIR) reported a Q4 loss of $0.09 per share for the quarter ended March 2025, significantly outperforming the Zacks Consensus Estimate of a $0.14 loss and improving substantially from a loss of $0.36 per share in the prior-year quarter. This result marked an earnings surprise of 35.71% and represented the fourth consecutive quarter in which the company surpassed consensus EPS estimates. However, XAIR's Q4 revenues of $1.15 million, though up from $0.47 million year-over-year, fell short of the Zacks Consensus Estimate by 17.12%. This continues a trend where the company has topped consensus revenue estimates only once in the last four quarters. Reflecting these mixed results and broader challenges, Beyond Air's shares have declined approximately 49.9% since the beginning of the year, starkly underperforming the S&P 500's 2.6% gain. The pre-release earnings estimate revision trend for XAIR was mixed, contributing to its current Zacks Rank #3 (Hold), which suggests the stock is anticipated to perform in line with the market in the near term. The Medical - Biomedical and Genetics industry, to which XAIR belongs, is currently ranked in the top 35% of over 250 Zacks industries. Future stock trajectory will largely hinge on management's commentary during the upcoming earnings call and subsequent shifts in consensus estimates, which currently project a loss of $0.12 per share on $1.99 million in revenue for the next quarter, and a loss of $0.42 per share on $13.66 million in revenue for the current fiscal year.

Key Decisions for Investors

• Investors should closely analyze management's discussion on the earnings call for specific strategies to address the recurring revenue shortfalls and build a consistent path to achieving top-line growth targets.
• Given the Zacks Rank #3 (Hold), significant year-to-date stock depreciation, and mixed operational results (EPS beat vs. revenue miss), a cautious approach is warranted; monitor for positive shifts in earnings estimate revisions before making significant investment decisions.
• Evaluate the sustainability of the improved EPS in light of the persistent revenue misses, and assess whether future revenue forecasts ($1.99 million next quarter, $13.66 million current fiscal year) adequately justify the current valuation and risk profile.